Assessing menopausal status in women aged 40 - 49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception. by Beksinska, Mags E et al.
Beksinska, ME; Smit, JA; Kleinschmidt, I; Farley, TMM (2011) As-
sessing menopausal status in women aged 40-49 using depot-medroxyprogesterone
acetate, norethisterone enanthate or combined oral contraception.
South African Medical Journal, 101 (2). pp. 131-135. ISSN 0256-
9574
Downloaded from: http://researchonline.lshtm.ac.uk/906/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/3.0/
131
ORIGINAL ARTICLES
February 2011, Vol. 101, No. 2  SAMJ
26.    Olin P, Hallander HO. Marked decline in pertussis followed reintroduction of pertussis vaccination in 
Sweden. Euro Surveill 1999;4(12):128-129.
27.    Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden with enhanced 
follow-up of cohorts immunized with acellular pertussis vaccines. 2009. Appendix 2. http://www.
smittskyddsinstitutet.se/upload/Publikationer/11-y-report-app202-GSK.pdf (accessed 15 December 
2010).
28.    Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with 
acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 
years of age. Pediatrics 2006;118(3):978-984.
29.    Pavlov DN, Van Zyl WB, Van Heerden J, et al. Prevalence of vaccine-derived polioviruses in stools of 
immunodeficient children in South Africa.  J Appl Microbiol 2006;101(6):1367-1379.
30.    Global Polio Eradication Initiative – Strategic Plan 2009 - 2013. http://www.polioeradication.org/
content/publications/PolioStrategicPlan09-13_Framework.pdf (accessed 19 October 2010).
31.    von Gottberg A, de Gouveia L, Madhi SA, et al. Impact of conjugate Haemophilus influenzae type b 
(Hib) vaccine introduction in South Africa. Bull World Health Organ 2006;84(10):811-818.
32.    Gold R, Scheifele D, Barreto L, et al. Safety and immunogenicity of Haemophilus influenzae vaccine 
(tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, 
pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of 
age. Pediatr Infect Dis J 1994;13(5):348-355.
33.    Lagos R, Horwitz I, Toro J, et al.  Large scale, postlicensure, selective vaccination of Chilean infants with 
PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae 
type b infections. Pediatr Infect Dis J 1996;15(3):216-222.
34.    Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ. The first five years of 
universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 
5-year-olds. Vaccine 2001;19(28-29):3919-3926.
35.    Clark A, Sanderson C. Timing of children’s vaccinations in 45 low-income and middle-income 
countries: an analysis of survey data. Lancet 2009;373(9674):1543-1549.
36.    Guerra FA. Delays in immunization have potentially serious health consequences.  Paediatr Drugs 
2007;9(3):143-148.
Accepted 12 November 2010.
Determining the onset of menopause in older users of hormonal 
injectable contraceptives depot medroxyprogesterone acetate 
(DMPA) and norethisterone enanthate (NET-EN) can be challenging. 
These contraceptive methods may mask menopausal symptoms such 
as amenorrhoea, which is a common side-effect of the method itself 
and increases in incidence over length of time used.1 DMPA has been 
shown to relieve vasomotor symptoms in perimenopausal women.2,3 
Furthermore, DMPA and NET-EN are known to suppress the mid-
cycle surge of follicle-stimulating hormone (FSH) and luteinising 
hormone (LH), thereby reducing raised FSH levels, although the 
tonic release of these gonadotrophins continues at luteal phase levels.4 
Detection of menopause or perimenopause may, therefore, present 
difficulties in this group of contraceptive users. In older combined 
oral contraceptive (COC) users, it is recommended that FSH is 
measured on the seventh day of the pill-free interval.5 However, 
appropriate advice for DMPA and NET-EN users is less clear, and it 
has been suggested that the options are to continue using the method 
until the woman reaches 55 years or to change to a non-hormonal 
method of contraception.6
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Assessing menopausal status in women aged 40 - 49 using 
depot-medroxyprogesterone acetate, norethisterone enanthate 
or combined oral contraception
Mags E Beksinska, Jenni A Smit, Immo Kleinschmidt, Tim M M Farley
Background. Determining symptoms of menopause in older users 
of hormonal injectable contraceptives may be challenging, owing to 
method-induced amenorrhoea, suppression of follicle-stimulating 
hormone (FSH) and vasomotor symptoms.
Objective. To investigate menopausal symptoms in women aged 
40 - 49 using injectable contraceptives depot-medroxyprogesterone 
acetate (DMPA), norethisterone enanthate (NET-EN) or combined 
oral contraceptives (COCs), compared with non-users of hormonal 
contraception.
Methods. Women using DMPA (N=127), NET-EN (N=102), 
COCs (N=106) and 161 non-hormonal contraceptive user controls 
were recruited. Baseline visit serum FSH was measured and 
information was collected on vasomotor symptoms and menstrual 
regularity.
Results. There was no difference in reporting of vasomotor 
symptoms between the groups. There was no evidence of a 
difference in FSH level between non-users (mean FSH 26.7 IU/ml, 
SD 28.7) and DMPA users (mean FSH 23.1 IU/ml, SD 27.8) 
(p=0.64). However, the NET-EN (mean FSH 11.0 IU/ml, SD 10.9) 
(p=0.003) and COC groups (mean FSH 12.5 IU/ml, SD 18.7) 
(p=0.001) had significantly lower FSH levels compared with the 
non-user group.
Conclusion. The lower FSH levels found in the NET-EN and 
COC users compared with controls may indicate a greater degree 
of suppression of FSH levels in these two methods, compared with 
DMPA. Measuring FSH levels may therefore be informative of 
menopausal status in DMPA users but not in NET-EN or COC 
users. Vasomotor symptoms may assist in assessing menopausal 
status in DMPA, NET-EN and COC users.
S Afr Med J 2011;101:131-135. 
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In South Africa, 63.1% of women aged 40 - 44 and 57.2% aged 45 - 
49 use contraception.7 Of these women approximately one-third use 
injectable contraceptives DMPA or NET-EN. Less women (10%) use 
COCs.7 While our primary aim was to study bone density in older 
women using hormonal contraceptives, a secondary objective was to 
investigate the menopausal status in participants who used hormonal 
contraception. This article presents the baseline results of the latter 
component of the study.
Subjects and methods
A cohort of women aged 40 - 49 were recruited from a large family 
planning clinic in Durban. Eligible participants had used a hormonal 
method of contraception for at least 1 year (hormonal user group) or had 
not used a hormonal method for at least 5 years (non-user group), had 
not lactated or delivered in the past 6 months, had never used medication 
known to affect calcium metabolism for more than 3 months, and did 
not have a chronic disease affecting calcium metabolism. Women who 
had amenorrhoea for at least 1 year were excluded.
On recruitment, a questionnaire was administered to elicit 
information on lifetime contraceptive history, fertility history, 
menopausal symptoms (hot flushes, night sweats, skin changes 
and dry vagina in last 3 months) and menstrual cycle regularity. 
Questions were also asked on smoking, diet, exercise and caffeine 
and alcohol intake.
Hormones and assays
A blood sample was drawn on the day of recruitment regardless of 
timing of the menstrual cycle or injection/COC dosage interval. 
Many women were experiencing irregular menstrual cycles owing 
to the use of injectable hormonal contraception or perimenopause. 
Consequently, a blood draw in the early follicular phase of the 
menstrual cycle was not specified.
Serum FSH levels were determined by immunoassay on the Roche 
Modular Analytics E170 (Elecsys module) immunoassay analyser. 
A FSH level ≥25.8 milli-international units per millilitre (mIU/ml) 
was considered to be in the menopausal range (King Edward VIII 
Hospital, Durban; Chemical Pathology Laboratory criteria using 
Roche Elecsys FSH expected values).
Assay specificity
Regarding analytical specificity, the following cross-reactions with 
other hormones have been determined for the monoclonal antibody 
used: luteinising hormone, thyroid-stimulating hormone, human 
chorionic gonadotropin, human growth hormone and human 
placental lactogen at <0.1%.
Assay sensitivity
The lower detection limit is <0.10 mIU/ml. The maximum of the 
measuring range is 200 mIU/ml. Values above this figure are reported 
as >200 mIU/ml.
Test precision (reproducibility)
The within-assay coefficients of variation ranged between 0.78% and 
1.5% for quality control samples with mean values of 9.53 and 33 mIU/
ml. Studies have shown that DMPA and NET-EN suppresses raised 
FSH and LH levels in perimenopausal and postmenopausal women 
in the early phase of the injection cycle; however, the suppressed 
levels almost always remained in the menopausal range.8,9
To investigate whether DMPA and NET-EN interfered with the 
FSH assay, control test samples and patient samples with high and 
low values of FSH were spiked with both contraceptives at levels 
above the highest circulating levels of MPA and NET described in the 
literature.10 Only very small differences were observed, which fell into 
the quoted within-run precision of the test.
Measurements
The examination included height, weight, blood pressure and 
waist and hip measurements using a standard protocol. Body mass 
index (BMI) was calculated from the weight and height as kg/m2. 
Participants were followed-up at 6-monthly intervals for a total of 
5 years. Our findings are based on the baseline data collected at 
recruitment and are cross-sectional in nature.
The characteristics of women in the study were quantified as means 
(±SD), or percentages. Differences in characteristics between the 
contraceptive groups were assessed using one-way analysis of variance. 
FSH levels were in addition classified into 2 categories according to 
laboratory cut-off levels for premenopausal (<25.8 mIU/ml) and peri-
menopausal/menopausal (≥25.8 mIU/ml). The effect of DMPA and 
NET-EN on the menstrual cycle meant that perimenopause could not 
be indicated by amenorrhoea in these hormonal contraceptive users. 
We therefore classified menopausal status using FSH and vasomotor 
symptoms. Women with an FSH outside the normal range and with 
at least one vasomotor symptom reported in the last 3 months were 
classified as perimenopausal. The association between vasomotor 
symptoms and contraceptive method user group was assessed using 
chi-square analysis and adjusted for age using logistic regression 
analysis. The association between FSH level and user group, adjusted 
for age, was estimated by using multiple variable linear regression. The 
study was powered to detect differences in bone mass between users 
and non-users of hormonal contraceptives; detailed methodology for 
this study is described elsewhere.11
Data were analysed using the statistical package STATA (V.10 College 
Station, TX, USA). Recruitment commenced in 2000 and was completed 
in 2003. The study was completed in 2007. Women were informed about 
the study and, if they were interested in volunteering to participate, 
they were asked to give written informed consent. Ethical approval 
was granted by the University of the Witwatersrand, Human Subjects 
Research Committee (Protocol Number M981001), and by the Scientific 
and Ethical Review Group of the World Health Organization.
Results
Socio-demographic and lifestyle 
characteristics of subjects
A total of 496 women were recruited. There were some differences 
between the characteristics of the 4 groups in the 40 - 49-year age 
group (Table I). Most women presenting as non-users tended to 
be >45 years, resulting in this group being on average 2 years older 
than the 3 user groups (p<0.001). There were a similar proportion 
of African women in both the injectable and non-user groups, but 
there was a significant difference in the composition of the COC 
group, where 26% were Indian women. Across all groups, few women 
exercised, and none in the 2 injectable groups reported following a 
diet in the last 6 months. Less than a fifth of the women had ever 
smoked, and few were current smokers.
Reproductive characteristics
Reproductive characteristics are shown in Table II. Age of menarche 
was around 15 years, and parity was between 3 and 4. The majority of 
women had used their group method for over 3 years at recruitment, 
and most were long-term users of the study methods.
Menopausal status
All FSH samples analysed for this study were above the lower 
detection limit, and no sample >200 mIU/ml was reported. FSH level 
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was associated with age, with an increase of 3.19 IU/ml (p≤0.0001) 
per year of age (40 - 49) for all groups combined. The FSH levels 
were significantly lower (p≤0.0001) in the NET-EN users and COC 
users compared with the controls (Table III). There was, however, no 
difference between the DMPA users and the controls (p=0.2). After 
adjusting the FSH level for age, the difference between the NET-EN 
Table I. Socio-demographic and lifestyle characteristics of subjects in the 40 - 49-year age range by contraceptive method use
Characteristics DMPA (N=127) NET-EN (N=102) COC (N=106)
Non-user controls 
(N=161) p value
Mean age, years (SD) 43.6 (2.7) 43.0 (2.2) 43.6 (2.6) 45.4 (2.5) <0.0001
Mean highest 
education grade (SD)
8.5 (3.3) 9.8 (3.1) 9.8 (2.4) 9.1 (2.7) 0.012
Marital status (%)
    Married/cohabiting 46.1 52.1 57.1 41.0 <0.0001
     Regular partner – 
not cohabiting
3.2 7.7 5.7 3.7
    Casual partner 38.9 36.5 28.6 25.5
    No partner 11.9 2.9 7.6 29.8
Employment status %
     Employed full/
part-time
44.5 73.5 71.5 63.4 <0.0001
    Unemployed 54 19.6 23.8 33.5
    Housewife 1.6 6.9 4.8 3.1
Ethnicity %
    Black 98.4 95.2 67.0 94.4 <0.0001
    Coloured 1.6 1.0 7.5 2.5
    Indian 0 3.8 25.5 3.1
Exercise
     No regular exercise 
(%)
96.9 96.0 94.3 93 0.48
     At least once a 
week (%)
3.1 4.0 5.7 7
Dieted in last 6 
months (%)
0 0 4.7 <1 0.003
Ever smoked 
cigarettes (%)
11.0 10.3 10.4 16.1 0.17
Current smoker (%) 4.7 5.6 5.7 9.9 0.23
DMPA = depot-medroxyprogesterone acetate; NET-EN = norethisterone enanthate; COC= combined oral contraceptive; SD = standard deviation.
Table II. Reproductive characteristics of subjects in the 40 - 49-year age group by contraceptive method
    DMPA  NET-EN  COC  Nonuser
Characteristics   (N=127)  (N=102)  (N=106)  (N=161)  p value
Mean parity (SD)   3.6+1.6  2.9+1.5  2.7+1.4  3.3+1.7  0.0001
Ever lactated (%)   88.2  91.3  87.7  83.2  0.34
Mean lactation (years, SD)  4.6+3.9  3.7+3.2  3.0+3.0  4.0+4.4  0.02
Mean age at menarche(years, SD) 15.2+ 1.7  15.5+1.7  14.8+1.7  14.8+1.6  0.014
Use of group method*          <0.0001
  Median use in last 5 yrs (months) 53  45  52  NA
  Median lifetime use (months)  84  49  89  NA
  Mean age at first use (years)  36  37  36  NA
*Only group method shown i.e. group to which women using that method at the time of recruitment were allocated. Contraceptive history of non-user group not shown (none had used a hormonal 
method in the year preceding recruitment).
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and COC users compared with the non-users persisted (p=0.003 and 
0.001 respectively) and there was no evidence of a difference between 
the DMPA users and non-users (p=0.64).
Table IV shows the proportion of women experiencing menopausal 
symptoms in each group. Although FSH levels were found to be lower 
in the COC and NET-EN groups, there was no evidence of a difference 
in the proportion  of women falling into the perimenopausal FSH 
range compared with controls after adjusting for age (DMPA p=0.51; 
NET-EN p=0.16; COC p=0.06). The non-user group experienced a 
higher proportion of night sweats; however, after adjusting for age, 
we found no difference in reporting symptoms between hormonal 
contraceptive users and non-users. In total, 48.5% of women in the 
non-user group were classified as perimenopausal (reported at least 
one vasomotor symptom in the last 3 months and had an FSH in the 
perimenopausal/menopausal range). This was a higher proportion 
than in the other 3 groups (40.2% DMPA, 31.4% NET-EN, 30.1% 
COCs); however, after adjusting for age, there was no evidence of 
a difference between the 4 groups in terms of menopausal status 
(DMPA p=0.48; NET-EN p=0.93; COC p=0.29) (Table IV).
Only 19.7% of women in the DMPA group and 33% of the NET-EN 
group reported a regular menstrual cycle (between 21 and 35 days), 
compared with 90% of the COC group and 93% of the non-users. 
Although there was no age difference between the ethnic groups 
(p=0.28). The Indian and coloured women had lower FSH values 
(9.6 IU/ml and 16.6 IU/ml respectively) compared with black women 
(20.5 IU/ml) (p=0.03).
Discussion
After adjusting for age, we found no difference in reporting of 
vasomotor symptoms between the hormonal contraceptive users 
and non-users. DMPA has been used successfully to treat vasomotor 
symptoms2,3 and, in one study,4 vasomotor symptoms were relieved in 
96% of women treated with one dose of DMPA, the relief beginning 
within 4 - 7 days. Relief was sustained for between 8 and 20 weeks, 
with symptoms returning from around 2 months. In the study by 
Bullock et al.,2 89.5% of women experienced relief from vasomotor 
symptoms; however, in this study, women received a monthly 
Table IV. Association between menopausal symptoms and contraceptive method unadjusted and adjusted for age
Menopausal
symptoms           % (N)         Unadjusted OR* (95% CI)        Age adjusted OR (95% CI)
Night sweats
Non-users          16.8 (27)        1 (reference)         1 (reference)
DMPA           7.1 (9)        0.38 (0.17 - 0.84)         0.57 (0.25 - 1.29)
NET-EN          3.8 (4)        0.20 (0.07 - 0.58)         0.36 (0.12 - 1.12)
COC           8.5 (9)        0.46 (0.21 - 1.02)         0.70 (0.30 - 1.60)
Hot flushes
Non-users          10.2 (13)        1 (reference)         1 (reference)
DMPA           3.8 (4)        0.59 (0.29 - 1.21)         0.87 (0.41 - 1.83)
NET-EN          8.5 (9)        0.21 (0.07 - 0.61)         0.36 (0.12 - 1.10)
COC           16.2 (26)        0.48 (0.22 - 1.07)         0.70 (0.31 - 1.61)
Skin changes
Non-users          18.9 (24)        1 (reference)         1 (reference)
DMPA           19.0 (20)        0.81 (0.45 -1.44)         1.04 (0.57 - 1.89)
NET-EN          27.4 (29)        0.82 (0.44 - 1.51)         1.16 (0.60 - 2.23)
COC           22.4 (36)        1.31 (0.74 - 2.30)         1.69 (0.94 - 3.07)
Dry vagina
Non-users          2.4 (3)        1 (reference)         1 (reference)
DMPA           1.9 (2)        0.21 (0.06 - 0.77)         0.27 (0.76 - 0.99)
NET-EN          3.8 (4)        0.18 (0.04 - 0.78)         0.24 (0.05 - 1.14)
COC           9.9 (16)        0.36 (0.12 - 1.09)         0.45 (0.14 - 1.41)
FSH >20 mIU/ml (%)
Non-users          37.7 (39)        1 (reference)         1 (reference)
DMPA           31.0 (17)        0.74 (0.45 - 1.21)         1.20 (0.70 - 2.07)
NET-EN          16.8 (19)        0.33 (0.18 - 0.62)         0.62 (0.32 - 1.20
COC           18.5 (60)        0.37 (0.21 - 0.67)         0.54 (0.29 - 1.02)
Perimenopausal**(%)
Non-users          48.5 (78)        1 (reference)         1 (reference)
DMPA           40.2 (51)        0.71 (0.45 - 1.14)         1.21 (0.72 - 2.04)
NET-EN          31.4 (33)        0.49 (0.29 - 0.82)         0.97 (0.55 - 1.73)
COC           30.5 (32)        0.47 (0.28 - 0.78)         0.74 (0.42 - 1.30)
*Odds ratio
**Menopausal status: Women were classified as perimenopausal if they reported at least one vasomotor symptom in last 3 months and had an FSH above the normal range (≥20.0 mIU/ml).
Table III. Mean FSH by users group
Study group N Mean FSH IU/ml (95% CI)
Non-users  161 26.7 (22.9 - 30.4) reference
DMPA  127 23.1 (18.9 - 27.3); p=0.2
NET-EN  102 10.9 (6.2 - 15.6); p≤0.0001
COC  106 12.5 (7.8 - 17.1); p≤0.0001
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injection of DMPA (150 mg) which is more frequent than the dose 
used for contraceptive purposes. In our study, we asked about any 
episode of vasomotor symptoms in the last 3 months; however, the 
study was not set up to collect frequency within that time period. 
It might have been that women in our study using DMPA were 
relieved of symptoms in the first 2 months of the injection cycle but 
symptoms returned towards the end of the 3-month injection cycle. 
This requires further investigation. There are no data on NET-EN 
and suppression of vasomotor symptoms, which may be because the 
method is not as widely used as DMPA. However, this study shows 
slightly lower reporting of night sweats in NET-EN compared with 
DMPA users, which may suggest that it also has the potential to 
relieve some vasomotor symptoms in women.
Our study found evidence that, although mean FSH was lower 
in NET-EN and COC users compared with DMPA and non-users 
after adjusting for age, there was no evidence of a difference in the 
proportion of each user group classified in the perimenopausal FSH 
range. COCs are known to suppress FSH levels to a greater extent 
than DMPA;12 however, limited information exists on NET-EN 
suppression of FSH in this age group. Ethnic differences in age at 
natural menopause could also be another possible explanation for 
the lower FSH levels in the COC group.13 This group comprised the 
highest proportion of Indian women (25.5%), and Indian women had 
significantly lower FSH than the black women of the same age, which 
adds to existing evidence that there are differences associated with 
ethnicity and age at natural menopause.13
In South Africa, alternatives to hormonal contraception such as 
sterilisation and the IUD are not readily accessible in the public 
health sector, and women will often continue to use hormonal 
injectables into their late 40s and beyond.7
Our study suggests that some women use hormonal contraception 
when they are in the menopausal transition. The variability of 
FSH levels during the perimenopause has called into question 
the reliability of using the FSH measure to diagnose or predict 
menopause.6 However, in hormonal injectable users, it may be one 
of the only means of assessing approaching menopause without 
discontinuing the method. This finding has important implications 
for guiding family planning providers, as South Africa has no 
guidelines on how to manage older injectable contraceptive users. In 
the public health sector, women are normally advised to remain on 
their methods until at least 50 years or until they report menopausal 
symptoms. In some cases, a single FSH measurement will be taken, 
normally after a method has been discontinued. Women could have 
FSH levels measured without discontinuing the method provided 
that the test is taken at the end of the injection cycle for both NET-EN 
and DMPA. A benefit to continuing use of injectables may be some 
relief of vasomotor symptoms associated with menopause.
Our study has several limitations. Cross-sectional in design, 
the data include only one FSH measurement where the timing of 
measurement was not always at the end of the injection cycle or 
7th day of the pill-free interval. Women were asked whether they 
had experienced any symptoms of menopause in the last 3 months, 
but the study was not set up to ask about the frequency of these 
symptoms over the 3-month period. However, the study indicates 
that menopausal symptoms and high FSH levels can be detected in 
some women, and this warrants further investigation with a larger 
sample size.
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